David Andes is an Infectious Disease physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 523 publications with 50,096 citations (h-index 111). By OpenAlex citation count, this profile ranks in the top 1% of Infectious Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 53792
Telephone
608-263-0943Provider last certified this registry record 14 Jan 2021.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20254 payments
- Melinta Therapeutics, LLCProgram year20251 payment
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
75.6%Macrolide Antimicrobial51.8%Azithromycin100%Part D≥94 patientsTetracycline-class Drug8.8%Doxycycline Hyclate100%Part D<11 patients+ 2 more classes in this area
Antiparasitic
24.4%Antimalarial24.4%Atovaquone-Proguanil Hcl100%Part D≥45 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi
University of Wisconsin-Madison
FY2026$777,498R01AI167883 - Vesicle-mediated drug resistance of Candida albicans biofilm
University of Wisconsin-Madison
FY2025$1,889,324R01AI073289 - Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi
University of Wisconsin-Madison
FY2025$763,891R01AI167883
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Albertini, MD
University of Wisconsin–Madison
Bryn Webb, MD
University of Wisconsin–Madison
Jeannina Smith, MD
University of Wisconsin–Madison
Carolina Pusec, PhD, MD
University of Wisconsin–Madison
Yousef Khader
Jordan University of Science and Technology
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Derrick W. Crook
Nuffield Orthopaedic Centre
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”